Short answer
Celcuity Inc. (CELC) filed an 8-K current report with the SEC on August 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results for quarter ended June 30, 2026.
Celcuity Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1 contains the substantive financial details
Item EX-99.1 · Exhibit EX-99.1
- FDA approval and Category 1 NCCN recommendation position REVTORPYK for commercial launch in late third quarter 2026
- VIKTORIA-1 mutant cohort doubled median PFS to 11.1 months versus 5.6 months, supporting planned third-quarter sNDA submission
- Convertible notes generated $557.2M net proceeds; $137.0M repaid term debt, extending funding runway into 2029
- Second-quarter net loss widened to $78.9M from $45.3M as launch-related SG&A rose to $35.0M from $7.6M
- Cash used in operations reached $55.4M; cash, equivalents and short-term investments totaled $754.0M at June 30, 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Celcuity Inc. 8-K filings
Get the next CELC 8-K as it lands
Follow CELC for push alerts, or ask the research agent what this filing means.